These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37724756)

  • 1. Long-term follow-up results of multiparametric prostate MRI and the prognostic value of PI-RADS: a single-center retrospective cohort study.
    Önder Ö; Ayva M; Yaraşır Y; Gürler V; Yazıcı MS; Akdoğan B; Karaosmanoğlu AD; Karçaaltıncaba M; Özmen MN; Akata D
    Diagn Interv Radiol; 2024 May; 30(3):139-151. PubMed ID: 37724756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer.
    Chu CE; Cowan JE; Lonergan PE; Washington SL; Fasulo V; de la Calle CM; Shinohara K; Westphalen AC; Carroll PR
    Eur Urol Oncol; 2022 Oct; 5(5):537-543. PubMed ID: 33483265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate.
    Boschheidgen M; Schimmöller L; Doerfler S; Al-Monajjed R; Morawitz J; Ziayee F; Mally D; Quentin M; Arsov C; Albers P; Antoch G; Ullrich T
    Sci Rep; 2022 Apr; 12(1):6746. PubMed ID: 35469056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
    Lim CS; Abreu-Gomez J; Carrion I; Schieda N
    AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
    [No Abstract]   [Full Text] [Related]  

  • 5. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations?
    Junker D; Steinkohl F; Fritz V; Bektic J; Tokas T; Aigner F; Herrmann TRW; Rieger M; Nagele U
    World J Urol; 2019 Apr; 37(4):691-699. PubMed ID: 30078170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
    Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX
    Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079
    [No Abstract]   [Full Text] [Related]  

  • 8. The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.
    Wang ZB; Wei CG; Zhang YY; Pan P; Dai GC; Tu J; Shen JK
    Biomed Res Int; 2021; 2021():3995789. PubMed ID: 34671673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
    Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
    World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men.
    Russo F; Mazzetti S; Regge D; Ambrosini I; Giannini V; Manfredi M; De Luca S; Bollito E; Porpiglia F
    Eur Urol Oncol; 2021 Dec; 4(6):855-862. PubMed ID: 33893066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective PI-RADS v2.1 Atypical Benign Prostatic Hyperplasia Nodules With Marked Restricted Diffusion: Detection of Clinically Significant Prostate Cancer on Multiparametric MRI.
    Costa DN; Jia L; Subramanian N; Xi Y; Rofsky NM; Recchimuzzi DZ; de Leon AD; Arraj P; Pedrosa I
    AJR Am J Roentgenol; 2021 Aug; 217(2):395-403. PubMed ID: 32876473
    [No Abstract]   [Full Text] [Related]  

  • 12. Low PI-RADS assessment category excludes extraprostatic extension (≥pT3a) of prostate cancer: a histology-validated study including 301 operated patients.
    Alessi S; Pricolo P; Summers P; Femia M; Tagliabue E; Renne G; Bianchi R; Musi G; De Cobelli O; Jereczek-Fossa BA; Bellomi M; Petralia G
    Eur Radiol; 2019 Oct; 29(10):5478-5487. PubMed ID: 30887199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic capabilities and clinical utility of cell cycle progression testing, prostate imaging reporting and data system, version 2, and clinicopathologic data in management of localized prostate cancer.
    Morris DS; Woods JS; Edwards B; Lenz L; Logan J; Flake DD; Mabey B; Bishoff JT; Cohen T; Stone S
    Urol Oncol; 2021 Jun; 39(6):366.e19-366.e28. PubMed ID: 33257218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of clinically significant prostate cancer using biparametric magnetic resonance imaging: An evolving concept.
    Mahajan M; Gupta V; Gupta P; Sharma P; Abrol D
    J Cancer Res Ther; 2022; 18(6):1640-1645. PubMed ID: 36412424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
    Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
    BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Multiparametric Magnetic Resonance Imaging in Detection and Prediction of Prostate Cancer.
    Wang R; Wang H; Zhao C; Hu J; Jiang Y; Tong Y; Liu T; Huang R; Wang X
    PLoS One; 2015; 10(6):e0130207. PubMed ID: 26067423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which men with non-malignant pathology at magnetic resonance imaging-targeted prostate biopsy and persistent PI-RADS 3-5 lesions should repeat biopsy?
    Castellani D; Pace G; Cecchini S; Franzese C; Cicconofri A; Romagnoli D; Del Rosso A; Possanzini M; Paci E; Dellabella M; Pierangeli T
    Urol Oncol; 2022 Oct; 40(10):452.e9-452.e16. PubMed ID: 35871992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Application of dynamic contrast enhanced status in multiparametric magnetic resonance imaging for prostatic cancer with PI-RADS 4 lesion].
    Yuan CW; Li R; Li ZH; Liu Y; Shan GZ; Li XS; Zhou LQ
    Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Oct; 55(5):838-842. PubMed ID: 37807737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?
    Roscigno M; Stabile A; Lughezzani G; Pepe P; Galosi AB; Naselli A; Naspro R; Nicolai M; La Croce G; Aljoulani M; Perugini G; Guazzoni G; Montorsi F; Balzarini L; Sironi S; Da Pozzo LF
    Clin Genitourin Cancer; 2020 Dec; 18(6):e698-e704. PubMed ID: 32493676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.